Joslin researchers show that caloric restriction lowers levels of innate immunity and inflammation, leading to increased longevity.

Scientists have known for decades that caloric restriction leads to a longer lifespan. It has also been observed that chronic inflammation increases with age. But any relationship between the two had remained unexplored.

But in a new study, published today in Cell Metabolism, researchers at Joslin Diabetes Center have uncovered a new mechanism of lifespan extension that links caloric restriction with immune system regulation.

“Modulating immune activity is an important aspect of dietary restriction,” says Keith Blackwell, MD, PhD, Associate Research Director and Senior Investigator at Joslin, and Professor of Genetics at Harvard Medical School, senior author on the paper. “And it is important for longevity regulation and, in this context, increasing lifespan.”

In this study, Dr. Blackwell and his team found that caloric restriction reduces levels of innate immunity by decreasing the activity of a regulatory protein called p38, triggering a chain reaction effect ending in a reduced immune response.

Modulating immune activity is an important aspect of dietary restriction, and it is important for longevity regulation and, in this context, increasing lifespan.

Keith Blackwell, MD, PHD Associate Research Director and Senior Investigator at Joslin

Innate immunity is like the security guard of the body, keeping an eye out for any unwelcome bacteria or viruses. If the innate immune system spots something, it activates an acute immune response. We need some degree of both kinds of immunity to stay healthy, but an overactive innate immune system—which occurs more often as we age—means constant low-grade inflammation, which can lead to myriad health issues.

“[Before this study,] people looked what happens to immunity to aging in humans, but no one had ever looked in any organism at whether modulating immunity or its activities is involved in lifespan extension or can be beneficial as part of an anti-aging program,” says Dr. Blackwell.

The research was conducted in the microscopic nematode worm C. elegans. The most fundamental genes and regulatory mechanisms found in these worms are typically simpler versions of those present in humans, making them a good model for studying human aging, genetics, and disease.

“This is really an emerging field in mammals now, so called immunometabolism—the idea that there are ancient links between metabolism and immunity,” says Dr. Blackwell. “We were able to show in this really very primitive immune system that it is regulated metabolically, and affects lifespan and health independently of an anti-pathogen function. That is when I started calling this a primitive immunometabolic pathway or an immunometabolic regulation.”

After making this discovery, Dr. Blackwell was curious to know if the well-known longevity mechanism of reduced IGF1 signaling also acted on the immune system. For over 20 years, study after study in many different organisms have confirmed that lower levels of IGF1 signaling contributes to a longer lifespan. This is thought to be due to the activation of protective factors by a protein called FOXO (called DAF-16 in C. elegans).

In this new study, Dr. Blackwell and his team discovered that when IGF signaling was reduced in the worms, the chain reaction set off by the FOXO-like DAF-16 not only boosted protective mechanisms, but also led to a reduction of the worms’ appetites. This naturally put the subjects in a state of caloric restriction.

“This links the growth mechanism [of IGF1 signaling] to food consumption and food seeking behavior in a big way,” says Dr. Blackwell.

A reduction in the activity of the FOXO-like gene seems to tell the worms that they are in a fasting-like state, and that nutrients may be scarce. This directs the worms to conserve energy, leading to a reduction in food intake. This self-imposed caloric restriction then leads to the lowering of the innate immune response. Dr. Blackwell plans to further study how the FOXO protein acts to suppress appetite, and to understand whether that might eventually lead to drug development.

The genes responsible for the phenomena observed in this study are conserved in humans. This opens up the possibility of human medical applications, from optimizing the immune system to drug development for appetite control.

“The ultimate goal is to be able to manipulate healthy lifespan in a person,” says Dr. Blackwell. “Not to make people live to 120, 130, but to extend the period of healthy life. And chronic inflammation is a major factor in human aging. The hope is that some of the specific mechanisms could translate to optimizing immune function in humans during aging to enhance health in human lifespan.”

The study was supported by grants from the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Related Articles

A man monitoring his blood sugar with glucose meter
Bariatric Surgery
Hypoglycemia
Research Highlights

New Closed-Loop System Offers Promise as Novel Treatment for Post-Bariatric Hypoglycemia

New Closed-Loop System Offers Promise as Novel Treatment for Post-Bariatric Hypoglycemia

The algorithm-controlled system senses impending lows and delivers small doses of liquid glucagon to raise blood sugar to safe levels­­. BOSTON - (January 9, 2020) - Gastric bypass vastly improves the...
Read more on New Closed-Loop System Offers Promise as Novel Treatment for Post-Bariatric Hypoglycemia
Doctor close up with arms crossed
Type 1
Type 2

Joslin Physicians on Boston Magazine's Top Docs List

Joslin Physicians on Boston Magazine's Top Docs List

Eleven of Joslin's physicians have made Boston Magazine’s 2020 Top Doctors List. Each year, Boston Magazine partners with healthcare researcher Castle Connolly Medical Ltd. to create a list of the...
Read more on Joslin Physicians on Boston Magazine's Top Docs List
Lloyd M. Aiello, M.D.
Type 1
Type 2
Eye Care

Tribute to Dr. Lloyd M. Aiello

Tribute to Dr. Lloyd M. Aiello

It is with great sorrow that we announce the passing of Lloyd M. Aiello, M.D., a pioneer in the treatment of diabetic retinopathy. Dr. Aiello died peacefully at age 87 at home on December 30, 2019...
Read more on Tribute to Dr. Lloyd M. Aiello